Ariad (ARIA) Stock | Will It Continue To Climb?

Ariad Pharmaceuticals Stock News ARIAAriad Pharmaceuticals, Inc. (NASDAQ: ARIA)

Ariad Pharmaceuticals stock climbed yesterday following the company’s announcement of preclinical data from 2 studies at the American Association for Cancer Research Annual Meeting 2015. The data was provided through two different presentations…

ARIA Preclinical Data Presentations

Oral Presentation on Brigatnib Discovery

This demonstration described the design and chemical structure of brigatinib. This data was discovered using a structure-based drug design platform that was developed by Ariad Pharmaceuticals. The scientists at ARIA advanced a series of compounds culminating in the identification of brigatnib. As a result of the unique chemical-design features seen in brigatnib, the drug has represented a much greater potency than the current industry leader, crizotinib, against ALK+ NSCLC cell lines and has been proven to be broadly active against crizotinib-resistant mutants in preclinical models.

Subscribe to The Prudent Speculator

New Preclinical Data on Brigatinib

This presentation showed that brigatinib has anti-tumor activity against a panel of 17 distinct ALK mutants known to confer resistance to other ALK inhibitors. In a separate study, brigatinib was proven to lower the tumor burden in mice with ALK+ brain tumors compared to the tumors in mice treated with crizotinib. Aside from a reduced tumor burden, survival rates in mice treated with brigatinib was proven to be substantially higher than in those treated with crizotinib.

What We Saw In The Market

As mentioned above, Ariad Pharmaceuticals stock climbed yesterday following the release of this information. After starting the day off at $9.04 per share, the stock climbed to more than $9.27 per share by the closing bell.

What We’re Seeing From ARIA Today

Today there seems to be a bit of a different story as the market is resisting any further growth. Currently (11:55), ARIA is trading at $9.27 after a series of inclines followed by declines have brought the stock to a point of no gain.

What We Can Expect Moving Forward

Moving forward, I’ve got incredibly high hopes for Ariad Pharmaceuticals stock. As seen in the data that was provided yesterday, the company continues to innovate and find ways to make the quality of life for those suffering with devastating ailments better. As more positive results come out from the amazing advances ARIA scientists continue to make in health care, we can only expect long term upward movement from this one!

What Do You Think?

Where do you think ARIA is headed and why? Let us know in the comments below!

Leave a Comment